Your browser doesn't support javascript.
loading
Seizures and Epilepsy After Stroke: Epidemiology, Biomarkers and Management.
Galovic, Marian; Ferreira-Atuesta, Carolina; Abraira, Laura; Döhler, Nico; Sinka, Lucia; Brigo, Francesco; Bentes, Carla; Zelano, Johan; Koepp, Matthias J.
Afiliação
  • Galovic M; Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland. marian.galovic@usz.ch.
  • Ferreira-Atuesta C; Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK. marian.galovic@usz.ch.
  • Abraira L; Chalfont Centre for Epilepsy, Chalfont St Peter, UK. marian.galovic@usz.ch.
  • Döhler N; Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK.
  • Sinka L; Chalfont Centre for Epilepsy, Chalfont St Peter, UK.
  • Brigo F; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Bentes C; Epilepsy Unit, Department of Neurology, Vall d'Hebron Hospital Universitari, Barcelona, Spain.
  • Zelano J; Universitat Autonoma de Barcelona, Bellaterra, Spain.
  • Koepp MJ; Specialist Clinic for Neurorehabilitation, Kliniken Beelitz, Beelitz-Heilstätten, Germany.
Drugs Aging ; 38(4): 285-299, 2021 04.
Article em En | MEDLINE | ID: mdl-33619704
ABSTRACT
Stroke is the leading cause of seizures and epilepsy in older adults. Patients who have larger and more severe strokes involving the cortex, are younger, and have acute symptomatic seizures and intracerebral haemorrhage are at highest risk of developing post-stroke epilepsy. Prognostic models, including the SeLECT and CAVE scores, help gauge the risk of epileptogenesis. Early electroencephalogram and blood-based biomarkers can provide information additional to the clinical risk factors of post-stroke epilepsy. The management of acute versus remote symptomatic seizures after stroke is markedly different. The choice of an ideal antiseizure medication should not only rely on efficacy but also consider adverse effects, altered pharmacodynamics in older adults, and the influence on the underlying vascular co-morbidity. Drug-drug interactions, particularly those between antiseizure medications and anticoagulants or antiplatelets, also influence treatment decisions. In this review, we describe the epidemiology, risk factors, biomarkers, and management of seizures after an ischaemic or haemorrhagic stroke. We discuss the special considerations required for the treatment of post-stroke epilepsy due to the age, co-morbidities, co-medication, and vulnerability of stroke survivors.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acidente Vascular Cerebral / Epilepsia Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Humans Idioma: En Revista: Drugs Aging Assunto da revista: GERIATRIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acidente Vascular Cerebral / Epilepsia Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Humans Idioma: En Revista: Drugs Aging Assunto da revista: GERIATRIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Suíça